healthcare-thumbnail.png

Diffuse Large B-Cell Lymphoma (DLBCL) Market Research Report

Published: 2025 - January

Report Code: VMR-17621

Region: Global

Request Sample
Customization
Ask an Expert
Enquire Enquire Before Buying

Diffuse Large B-Cell Lymphoma Market Analysis 

The Diffuse Large B-Cell Lymphoma (DLBCL) Market is centered around the diagnosis, treatment, and management of the most common type of non-Hodgkin lymphoma, characterized by its aggressive nature and rapid progression. This market focuses on advanced therapeutic modalities, including immunotherapy, targeted therapies, and CAR T-cell treatments, offering solutions that improve survival rates and quality of life for patients with DLBCL.

Disruptive Impact and Opportunities:

Emerging therapies such as Epcoritamab, Glofitamab, and AUTO 3 bring innovation with novel mechanisms like bispecific T-cell engagers and next-generation CAR T-cell therapies. Subcutaneous and oral formulations, like those under development, simplify drug administration and enhance patient compliance. Advanced therapies such as POLIVY (polatuzumab vedotin-piiq) and XPOVIO (selinexor) focus on targeted delivery to minimize adverse effects, addressing unmet patient needs. The growing number of approvals for CAR T-cell therapies like YESCARTA (axicabtagene ciloleucel) and KYMRIAH (tisagenlecleucel) highlights significant growth potential in precision oncology.

Diffuse Large B-Cell Lymphoma Market Segmentation - Emerging Drugs

  • Epcoritamab

  • Glofitamab

  • Acalabrutinib

  • AUTO 3

  • Abexinostat

Diffuse Large B-Cell Lymphoma Market Segmentation - Marketed Drugs

  • YESCARTA (axicabtagene ciloleucel)

  • KYMRIAH (tisagenlecleucel)

  • XPOVIO (selinexor)

  • POLIVY (polatuzumab vedotin-piiq)

Key Companies:

  • Genmab

  • Roche

  • Acerta Pharma

  • Autolus

  • Xynomic Pharmaceuticals

  • Genentech

  • Celgene

  • AbbVie

  • Mabion

  • Pharmacyclics LLC.

  • Shanghai Yingli Pharmaceutical

  • Philogen

  • Amgen

Diffuse Large B-Cell Lymphoma Market Segmentation -  By Type

·  Monoclonal Antibodies

  • Anti-CD20 Antibodies

  • Bispecific Antibodies

·  Chemotherapy Regimens

  • CHOP-based Regimens

  • Salvage Chemotherapy

·  Targeted Therapies

  • BTK Inhibitors

  • PI3K Inhibitors

·  CAR T-cell Therapies

·  Immunomodulatory Drugs (IMiDs)

  • Radiotherapy-Linked Drugs

  • Others

Diffuse Large B-Cell Lymphoma Market Segmentation -  By Administration Type

·  Oral

·  Intravenous

·  Subcutaneous

·  Others

What’s in It for You?

  • Deep analysis of innovative therapies and competitive pipelines.

  • Insights into market trends driving adoption of advanced treatments.

  • Strategic opportunities to benchmark against leading companies.

  • Tailored recommendations for investment in high-growth segments.

Diffuse Large B-Cell Lymphoma Market Analysis (Market Size & CAGR, Epidemiology, Marketed Therapies, Emerging Drugs, Clinical Trials, Key Approvals & Anticipated Loss of Exclusivity, Opportunities, Unmet Needs, Company Profiles)

1. Diffuse Large B-Cell Lymphoma Market - Executive Summary

               1.1. Introduction              

               1.2. Objectives  

               1.3. Key Findings              

                              1.3.1. Market Size 2022 & 2032: By Key Country (10MM)

                              1.3.2. Global Market Size 2022 & 2032: By Key Segment

                              1.3.3. Key Investments & Startup Analysis

               1.4. Research Methodology                               

2. Understanding the Disease     

               2.1. Disease Overview

               2.2. Classification             

               2.3. Signs and Symptoms

               2.4. Risk Factors

               2.5. Causes        

               2.6. Disease Biology & Digital Innovations

               2.7. Stages & Staging System

               2.8. Diagnostic Algorithm

               2.9. Current Treatment Practices & Algorithm

               2.10. Current Standard of Care and Treatment Gaps

               2.11. Patient Demographics and Treatment Pathways

3. Guidelines                                                                  

4. Unmet Needs                                

5. Epidemiology and Patient Population

               5.1. Epidemiology Key Findings

               5.2. Assumptions and Rationale: 10MM

               5.3. Epidemiology Scenario: 10MM

               5.4. U.S. Epidemiology Scenario

               5.5. EU-5 Epidemiology

                              5.5.1. U.K. Epidemiology Scenario

                              5.5.2. Germany Epidemiology Scenario

                              5.5.3. France Epidemiology Scenario

                              5.5.4. Italy Epidemiology Scenario

                              5.5.5. Spain Epidemiology Scenario

               5.6. Japan Epidemiology Scenario

               5.7. China Epidemiology Scenario

               5.8. Australia Epidemiology Scenario

               5.9. India Epidemiology Scenario                                   

6. Real-world Data & Real-world Evidence

7. Drug Development Landscape

               7.1. Existing Key Drug Candidate Profiles/ Marketed Therapies

                              7.1.1. YESCARTA (axicabtagene ciloleucel)

                                             7.1.1.1. Product Description

                                             7.1.1.2. Regulatory Milestones

                                             7.1.1.3. Other Developmental Activities

                                             7.1.1.4. Pivotal Clinical Trials

                                             7.1.1.5. Ongoing Current Pipeline Activity

                              7.1.2. KYMRIAH (tisagenlecleucel)

                                             7.1.2.1. Product Description

                                             7.1.2.2. Regulatory Milestones

                                             7.1.2.3. Other Developmental Activities

                                             7.1.2.4. Pivotal Clinical Trials

                                             7.1.2.5. Ongoing Current Pipeline Activity

                              7.1.3. XPOVIO (selinexor)

                                             7.1.3.1. Product Description

                                             7.1.3.2. Regulatory Milestones

                                             7.1.3.3. Other Developmental Activities

                                             7.1.3.4. Pivotal Clinical Trials

                                             7.1.3.5. Ongoing Current Pipeline Activity

                              7.1.4. POLIVY (polatuzumab vedotin-piiq)

                                             7.1.4.1. Product Description

                                             7.1.4.2. Regulatory Milestones

                                             7.1.4.3. Other Developmental Activities

                                             7.1.4.4. Pivotal Clinical Trials

                                             7.1.4.5. Ongoing Current Pipeline Activity

               7.2. Competitive Analysis and Differentiation

               7.3. Overview of Similar/Competing Drugs in Clinical Trials

               7.4. Future Trends and Emerging Drugs

                              7.4.1. Epcoritamab

                                             7.4.1.1. Product Description

                                             7.4.1.2. Clinical Development

                                             7.4.1.3. Safety and Efficacy

                              7.4.2. Glofitamab

                                             7.4.2.1. Product Description

                                             7.4.2.2. Clinical Development

                                             7.4.2.3. Safety and Efficacy

                              7.4.3. Acalabrutinib

                                             7.4.3.1. Product Description

                                             7.4.3.2. Clinical Development

                                             7.4.3.3. Safety and Efficacy

8. Regulatory Strategy and Potential Challenges

               8.1. Regulatory Pathways in Key Markets

               8.2. Anticipated Regulatory Hurdles and Mitigation Strategies

               8.3. Case Studies in Oncology Drug Regulation

               8.4. Impact of Potential Changes to Regulatory Framework

9. Commercial Landscape            

               9.1. Market Size & Growth Rates

               9.2. Key Approvals & Anticipated Loss of Exclusivity

               9.3. PESTLE & Porter’s Five Forces Analysis

               9.4. Market Shares, Positioning/Ranking

               9.5. Market Drivers         

               9.6. Identification of Threats

               9.7. Digital Evolution in Commercialization

10. Market Segmentation             

               10.1. Market by Therapy Type

                              10.1.1. Chemotherapy

                              10.1.2. Targeted Therapy

                              10.1.3. Others

11. Pricing, Reimbursement, and Access

               11.1. Competitive Pricing Analysis

               11.2. Reimbursement Landscape and Challenges

               11.3. Strategies for Market Access and Equity

               11.4. Patient Spending/Expenditure Analysis

12. Future Trends, Disruptions, and Opportunities

               12.1. Analysis of Emerging Trends

               12.2. Technological Impact

               12.3. Impact of Potential Market Disruptors

               12.4. Opportunities for Future Development and Expansion

               12.5. Considerations for Investment Opportunities

13. Global Market Dynamics       

               13.1. Regional Regulatory Disparities

               13.2. Cross-Border Partnership Strategies

               13.3. Global Supply Chain Dynamics

               13.4. Case Studies: Success and Failure in Global Markets

               13.5. Strategies for Global Expansion and Localization

14. Company Profiles     

               14.1. Seagen Inc.             

               14.2. Eisai Co Ltd             

               14.3. Nurix Therapeutics, Inc.

               14.4. Roche        

               14.5. AbbVie      

               14.6. Amgen      

               14.7. W Therapeutics

               14.8. Incyte Corporation

               14.9. Bristol-Myers Squibb

               14.10. Bayer     

Download Sample

↻

The field with (*) is required.

Choose License Type

$

2500

$

4250

$

5250

$

6900

Request Sample
Customization
Ask an Expert
Enquire Before Buying
customer-support

Analyst Support

Every order comes with Analyst Support.

report-custom

Customization

We offer customization to cater your needs to fullest.

verify

Verified Analysis

We value integrity, quality and authenticity the most.

© 2025 Virtue Market Research. All Rights Reserved.